澳大利亞研究者不久前通過小規(guī)模臨床試驗發(fā)現(xiàn),，歐洲常見的雜草“南歐大戟”的汁液可用于治療非色素瘤皮膚癌,，并且對一些不適合采用現(xiàn)有療法的患者有效。
非色素瘤皮膚癌是最常見的一類皮膚癌,，多發(fā)于老年人,，通常可用手術,、冷凍等手段治愈,，但對一部分患者無效，而且有些患者由于年齡等原因不適合采用這些療法。
澳大利亞研究人員在新一期《英國皮膚病學雜志》上報告說,，他們的試驗對象是36名非色素瘤皮膚癌患者,，現(xiàn)有療法對其中部分患者沒有療效，有的患者則拒絕或不適合采取現(xiàn)有療法,。
這些患者的皮膚上共有48處皮膚癌病灶,。在第一輪治療中，研究人員將南歐大戟的汁液涂抹在患處,，每天一次,，持續(xù)3天。一個月后,，有41處病灶出現(xiàn)“完全應答”,，即臨床檢驗發(fā)現(xiàn)腫瘤消失。只出現(xiàn)部分應答的患者接受了第二輪治療,。
完全應答意味著取得非常積極的療效,，但不表示徹底治愈，因為存在復發(fā)的可能,。然而跟蹤調(diào)查顯示,，平均15個月之后，約有三分之二的病灶仍呈現(xiàn)完全應答的效果,。
研究人員說,，這一結(jié)果顯示了南歐大戟汁液提取物在治療皮膚癌方面的前景，目前認為是其汁液中一種代號為PEP005的物質(zhì)發(fā)揮了作用,，今后將通過大規(guī)模研究來進一步驗證這種物質(zhì)的功效,。
南歐大戟是一種大戟科植物，廣泛分布于歐美等地,，是房前屋后或園林中常見的雜草,，中國也有分布。南歐大戟在歐洲被當作一種民間草藥由來已久,，用于治療皮膚病,、哮喘和癌癥等等。
不過專家提醒說,，普通人不應在家自行嘗試用南歐大戟的汁液來治療皮膚癌,，因為這項研究還處于試驗階段，并可能引起皮膚發(fā)炎等一些不良反應,。（生物谷Bioon.com）
生物谷推薦原文出處：
British Journal of Dermatology doi: 10.1111/j.1365-2133.2010.10184.x
The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers
J.R. Ramsay1, A. Suhrbier2,3, J.H. Aylward4, S. Ogbourne2, S.-J. Cozzi2, M.G. Poulsen1, K.C. Baumann1, P. Welburn4, G.L. Redlich4, P.G. Parsons2,3
Summary
Background The sap from Euphorbia peplus, commonly known as petty spurge in the U.K. or radium weed in Australia, has been used as a traditional treatment for a number of cancers.
Objective To determine the effectiveness of E. peplus sap in a phase I/II clinical study for the topical treatment of basal cell carcinomas (BCC), squamous cell carcinomas (SCC) and intraepidermal carcinomas (IEC).
Methods Thirty-six patients, who had refused, failed or were unsuitable for conventional treatment, were enrolled in a phase I/II clinical study. A total of 48 skin cancer lesions were treated topically with 100–300 μL of E. peplus sap once daily for 3 days.
Results The complete clinical response rates at 1 month were 82% (n = 28) for BCC, 94% (n = 16) for IEC and 75% (n = 4) for SCC. After a mean follow-up of 15 months these rates were 57%, 75% and 50%, respectively. For superficial lesions < 16 mm, the response rates after follow-up were 100% for IEC (n = 10) and 78% for BCC (n = 9).
Conclusions The clinical responses for these relatively unfavourable lesions (43% had failed previous treatments, 35% were situated in the head and neck region and 30% were > 2 cm in diameter), are comparable with existing nonsurgical treatments. An active ingredient of E. peplus sap has been identified as ingenol mebutate (PEP005). This clinical study affirms community experience with E. peplus sap, and supports further clinical development of PEP005 for the treatment of BCC, SCC and IEC.
